Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (Nasdaq:SNGX) and Sharps Technology Inc. (Nasdaq:STSS) on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, June 8, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
RedChip公司將於2024年6月7日在Bloomberg TV《Small Stocks, Big Money》贊助節目中播放Soligenix,Inc.(Nasdaq:SNGX)和Sharps Technology Inc. (Nasdaq:STSS)的採訪。Bloomberg TV在美國約有約7300萬戶家庭觀衆。《Small Stocks, Big Money》是贊助節目，將於6月8日晚上7點（美東時間）在Bloomberg TV上播出。觀衆可通過以下鏈接觀看完整訪談：
Access the interviews in their entirety at:
Soligenix:
- Soligenix:
- Sharps Technology:
- Sharps Technology:
- 在一次獨家採訪中，Soligenix的總裁兼首席執行官Christopher J. Schaber博士出現在Bloomberg TV的《Small Stocks Big Money》節目中，提供公司最新進展。Soligenix是一家後期生物製藥公司，擁有多個處於先進臨床階段的產品組合，目標銷售額達20億美元。其中最引人注目的是HyBryte，一種針對罕見慢性癌症皮膚T細胞淋巴瘤（CTCL）的光動力療法，它在《JAMA皮膚科學》上發表的第3階段研究中表現出積極的結果。公司正在積極籌備跟進的確證性第3階段研究，HyBryte的市場潛力估計達2.5億美元。其他有前途的資產包括SGX302，旨在治療牛皮癬，目前正在進行第2a階段試驗，市場潛力超過10億美元，以及針對兒童克羅恩病的SGX203，正在等待進一步的資金支持進行第3階段試驗。
In an exclusive interview, Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix, appears on the RedChip Small Stocks Big Money show on Bloomberg TV to provide a corporate update. Soligenix, a late-stage biopharmaceutical company, showcases a strong portfolio with several products in advanced clinical stages, targeting a potential $2 billion in annual global sales. Notable among these is HyBryte, a photodynamic therapy for cutaneous T-cell lymphoma (CTCL), a rare chronic cancer, which has demonstrated positive results in a Phase 3 study published in JAMA Dermatology. The company is gearing up for a follow-up confirmatory Phase 3 study, with HyBryte's market potential estimated at $250 million. Additional promising assets include SGX302, aimed at treating psoriasis, currently in Phase 2a trials with a market potential exceeding $1 billion, and SGX203 for pediatric Crohn's disease, pending further funding for Phase 3 trials.
Soligenix的總裁兼首席執行官Christopher J.Schaber博士在RedChip上接受了獨家採訪。在Bloomberg TV的《Small Stocks Big Money》節目上，Sharps Technology的首席執行官Robert Hayes將提供公司的最新進展。Sharps Technology最近簽署了價值2億美元的五年銷售協議，並加強了資產購買協議，以收購Nephron Pharmaceuticals的InjectEZ設施。此次收購將使Sharps成爲北美第一個完全致力於專業聚合物預充填器製造商。該設施預計將於2025年第二季度開始交付產品，在頭12個月預計將產生超過3500萬美元的收入，到2026年有超過5千萬美元的可能性，到2028年有超過1億美元的可能性。近期的FDA召回和對中國注射器的關稅推動了對Sharps產品的需求，這些產品越來越受到青睞。Sharps正在與主要製藥公司、零售連鎖店和醫療保健分銷商合作，以擴大其市場份額。隨着實現了可觀的收入增長和盈利能力，再加上來自Aegis Capital的買入評級和16美元的股價目標，Sharps代表了一個引人注目的機會。Soligenix是一家晚期生物醫藥公司，在其強大的產品組合中擁有多個處於先進臨床階段的產品，目標是實現年銷售額20億美元。其中，在JAMA皮膚病學雜誌上發佈的3期研究中取得了積極效果的光動力療法（PDT）用於治療罕見慢性癌症——皮膚T細胞淋巴瘤（CTCL）的HyBryte特別值得一提。該公司正在籌備跟進確認性3期研究，HyBryte的市場潛力估計爲2.5億美元。另外有希望的資產還包括治療牛皮癬的SGX302，目前正在進行2a期試驗，其市場潛力超過10億美元，以及用於兒科克隆病的SGX203，等待進一步的第3期試驗資金。
Robert Hayes, Chief Executive Officer of Sharps Technology, appears on the RedChip Small Stocks, Big Money show on Bloomberg TV to provide a corporate update. Sharps Technology recently signed a $200 million five-year Sales Agreement and enhanced its Asset Purchase Agreement to acquire Nephron Pharmaceuticals' InjectEZ facility. This acquisition will position Sharps as North America's first fully dedicated specialized polymer prefillable syringe manufacturer. The facility, set to begin product deliveries in Q2 2025, is expected to generate over $35 million in revenue in the first 12 months, with the potential to exceed $50 million by 2026 and $100 million by 2028. Recent FDA recalls and tariffs on Chinese syringes have boosted demand for Sharps' products, which are increasingly preferred over glass syringes. Sharps is engaging with major pharmaceutical companies, retail chains, and healthcare distributors to expand its market presence. With a clear path to substantial revenue growth and profitability, alongside a buy rating and $16 per share price target from Aegis Capital, Sharps represents a compelling opportunity.
在Bloomberg TV的《Small Stocks, Big Money》節目中，Sharps Technology的首席執行官Robert Hayes將提供公司的最新進展。《Small Stocks, Big Money》是贊助節目，將於6月8日晚上7點（美東時間）在Bloomberg TV上播出。Sharps Technology最近簽署了一份2億美元爲期5年的銷售協議，並增強了其資產購買協議，以收購Nephron藥品的InjectEZ設施。此次收購將使Sharps成爲北美第一家完全專注於專門的聚合物預填充注射器製造商。該設施預計將於2025年第二季度開始交付產品，首12個月預計將產生超過3500萬美元的收入，並有望在2026年超過5000萬美元，2028年超過1億美元。最近美國FDA的召回和中國注射器的關稅提高了對Sharps產品的需求，這些產品越來越受到人們的青睞，而不再是玻璃注射器。Sharps正在與主要藥品公司、零售連鎖店和醫療保健分銷商接觸，以擴大其市場地位。隨着可觀的營收增長和盈利能力的明顯路徑，以及Aegis Capital的買入評級和16美元每股的目標價，Sharps代表了一個引人注目的機會。
About Soligenix, Inc.
關於Soligenix, Inc. ：
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet's Disease.
Soligenix是一家後期生物製藥公司，專注於開發和商業化用於治療罕見疾病的產品。我們的特種生物治療業務部門正在開發並向潛在商業化邁進HyperBrite (SGX301或合成酸豆莢菜紅素鈉)，作爲一種利用安全可見光治療皮膚T細胞淋巴瘤(CTCL)的新型光動力療法。經過第二階段3研究的成功完成，將尋求監管批准支持全球潛在的商業化。該業務領域的開發計劃還包括將合成酸豆菜紅素(SGX302)擴展到牛皮癬、首創的天然防禦調節素(IDR)技術dusquetide(SGX942)治療炎性疾病，包括頭頸癌口腔炎，以及治療Behçet's疾病的SGX945。我們的公共衛生解決方案業務部門包括開發RiVax我們的蓖麻毒素疫苗候選者，以及針對非洲病毒（如馬爾堡病毒和埃博拉病毒）和CiVax我們的預防COVID-19（由SARS-CoV-2引起）疫苗候選者的疫苗計劃。在我們的疫苗計劃開發中，我們採用了我們自有的熱穩定平台技術ThermoVax。迄今爲止，該業務領域已獲得過來自美國過敏症和傳染病研究所（NIAID）、國防威脅削減署（DTRA）和生物醫藥高級研究和發展管理局（BARDA）的政府資助和合同資金支持。
Our Public Health Solutions business segment includes development programs for RiVax, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
欲了解更多關於Soligenix, Inc.的信息，請訪問公司的網站，並在LinkedIn和Twitter上關注我們@Soligenix_Inc。CiVax對於SARS-CoV-2所致COVID-19的疫苗候選者我們的疫苗計劃開發中，採用了我們自有的熱穩定平台技術ThermoVax。迄今爲止，該業務領域已獲得過來自美國過敏症和傳染病研究所（NIAID）、國防威脅削減署（DTRA）和生物醫藥高級研究和發展管理局（BARDA）的政府資助和合同資金支持。
For further information regarding Soligenix, Inc., please visit the Company's website at and follow us on LinkedIn and Twitter at @Soligenix_Inc.
欲了解更多關於Soligenix, Inc.的信息，請訪問公司的網站，並在LinkedIn和Twitter上關注我們@Soligenix_Inc。
About Sharps Technology
關於Sharp科技
Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the U.S. For additional information, please visit .
Sharps Technology是一家提供專利、最佳智能安全注射器產品的創新醫療器械和醫藥包裝公司。公司的產品系列專注於提供超低浪費功能，結合採用被動和主動安全功能的注射器技術。堅銳還提供專門的共聚物技術產品，以支持預填充注射器市場細分。該公司在匈牙利擁有一家制造工廠，並與Nephron Pharmaceuticals合作拓展其在美國的生產能力。有關詳細信息，請訪問 。
About RedChip Companies
關於RedChip公司
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip公司是一家國際投資者關係、媒體和研究公司，是一家美國《Inc.》雜誌5000強公司，專注於微型市值和小市值公司。32年來，RedChip爲客戶提供了具體、可衡量的成果。我們的新聞簡報，“小公司股票、大鈔票”，每週在線上向6萬投資者發送。RedChip已經開發出行業中最全面的服務平台，爲微型市值和小市值公司提供以下服務：股票研究的全球分銷網絡；在美國主要城市進行散戶和機構路演；外發營銷給股票經紀人、RIA、機構和家族辦公室；數字媒體投資者關係平台，爲股東帶來數百萬次獨特的投資者瀏覽量；投資者網絡研討會和集體電話；電視節目，“小公司股票、大鈔票”，每週在Bloomberg US播出；在地方和全國市場上的電視廣告；公司和產品視頻；網站設計；傳統投資者關係服務，包括新聞稿撰寫、投資者演示文稿的製作、季度電話會議劇本的編寫、戰略諮詢、融資等。小公司股票、大鈔票在線向6萬投資者每週發送的電子郵件新聞簡報，“小公司股票、大鈔票”小公司股票、大鈔票在Bloomberg US每週播出的電視節目“小公司股票、大鈔票”
To learn more about RedChip's products and services, please visit:
了解RedChip的產品和服務，請訪問：
"Discovering Tomorrow's Blue Chips Today"
“發現明日的藍籌股”
Follow RedChip on LinkedIn:
Follow RedChip on Facebook:
Follow RedChip on Instagram:
Follow RedChip on Twitter:
Follow RedChip on YouTube:
Follow RedChip on Rumble:
Subscribe to our Mailing List:
在LinkedIn上關注RedChip：
在Facebook上關注RedChip：
在Instagram上關注RedChip：
在Twitter上關注RedChip：
在YouTube上關注RedChip：
在Rumble上關注RedChip：
訂閱我們的郵件列表：
Contact:
聯繫方式：
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
SOURCE: RedChip Companies Inc.
資料來源： RedChip Companies Inc.
譯文內容由第三人軟體翻譯。